oleoylethanolamide
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Apr 6, 2021 (NCT04614233)
Timeline
No events for the selected filters.
Indications
Approved for
Studied for
Mechanism of action
- Cannabinoid CB1 receptorANTAGONIST
CNR1 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05252949 | N/A | Jun 10, 2021 | Department of Defense, Roskamp Institute |
| NCT04614233 | Phase 4 | Apr 6, 2021 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Yale University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Department of Defense | Government | 1 | 0 | 1 | 2021 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 1 | 0 | 1 | 2021 |
| Roskamp Institute | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2021 |
4 organizations
Page 1 / 1